郑荣寿 , 张思维 , 孙可欣 , 等 . 2016年中国恶性肿瘤流行情况分析 [J ] . 中华肿瘤杂志 , 2023 , 45 ( 3 ): 212 - 220 .

ZHENG R S , ZHANG S W , SUN K X , et al . Cancer statistics in China, 2016 [J ] . Chin J Oncol , 2023 , 45 ( 3 ): 212 - 220 .

MCCORMACK M , GALLARDO RINCÓN D , EMINOWICZ G , et al . A randomised phase Ⅲ trial of induction chemotherapy followed by chemoradiation compared with chemoradiation alone in locally advanced cervical cancer: the GCIG INTERLACE trial [J ] . Ann Oncol , 2023 , 34 : S1276 .

MILESHKIN L R , MOORE K N , BARNES E H , et al . Adjuvant chemotherapy following chemoradiotherapy as primary treatment for locally advanced cervical cancer versus chemoradiotherapy alone (OUTBACK): an international, open-label, randomised, phase 3 trial [J ] . Lancet Oncol , 2023 , 24 ( 5 ): 468 - 482 . DOI: 10.1016/S1470-2045(23)00147-X http://doi.org/10.1016/S1470-2045(23)00147-X

LORUSSO D , XIANG Y , HASEGAWA K , et al . Pembrolizumab plus chemoradiotherapy for high-risk locally advanced cervical cancer: a randomized, double-blind, phase Ⅲ ENGOT-cx11/GOG-3047/KEYNOTE-A18 study [J ] . Ann Oncol , 2023 , 34 : S1279 -S1280. DOI: 10.1016/j.annonc.2023.10.032 http://doi.org/10.1016/j.annonc.2023.10.032 https://linkinghub.elsevier.com/retrieve/pii/S0923753423041765 https://linkinghub.elsevier.com/retrieve/pii/S0923753423041765

MAYADEV J , NUNES A T , LI M , et al . CALLA: efficacy and safety of concurrent and adjuvant durvalumab with chemoradiotherapy versus chemoradiotherapy alone in women with locally advanced cervical cancer: a phase Ⅲ, randomized, double-blind, multicenter study [J ] . Int J Gynecol Cancer , 2020 , 30 ( 7 ): 1065 - 1070 . DOI: 10.1136/ijgc-2019-001135 http://doi.org/10.1136/ijgc-2019-001135 https://ijgc.bmj.com/lookup/doi/10.1136/ijgc-2019-001135 https://ijgc.bmj.com/lookup/doi/10.1136/ijgc-2019-001135

LEATH C A , DENG W , MELL L K , et al . Incorporation of triapine (T) with cisplatin chemoradiation (CRT) for locally advanced cervical and vaginal cancer: results from NRG-GY006, a phase Ⅲ randomized trial [J ] . J Clin Oncol , 2023 , 41 ( 16_suppl ): 5502 . DOI: 10.1200/JCO.2023.41.16_suppl.5502 http://doi.org/10.1200/JCO.2023.41.16_suppl.5502 https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.5502 https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.5502

COLOMBO N , DUBOT C , LORUSSO D , et al . Pembrolizumab for persistent, recurrent, or metastatic cervical cancer [J ] . N Engl J Med , 2021 , 385 ( 20 ): 1856 - 1867 . DOI: 10.1056/NEJMoa2112435 http://doi.org/10.1056/NEJMoa2112435 http://www.nejm.org/doi/10.1056/NEJMoa2112435 http://www.nejm.org/doi/10.1056/NEJMoa2112435

MONK B J , COLOMBO N , TEWARI K S , et al . First-line pembrolizumab+chemotherapy versus placebo+chemotherapy for persistent, recurrent, or metastatic cervical cancer: final overall survival results of KEYNOTE-826 [J ] . J Clin Oncol , 2023 : JCO2 300914.

LIU N , YANG Z , TANG D , et al . Efficacy and safety of QL1706 plus paclitaxel and cisplatin/carboplatin +/- bevacizumab (Bev) as 1L treatment in recurrent or metastatic cervical cancer (r/mCC): a single-arm, multicenter phase Ⅱ study [J ] . Ann Oncol , 2023 , 34 : S509 .

GAO X , XU N , LI Z , et al . Safety and antitumour activity of cadonilimab, an anti-PD-1/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b/2 trial [J ] . Lancet Oncol , 2023 , 24 ( 10 ): 1134 - 1146 . DOI: 10.1016/S1470-2045(23)00411-4 http://doi.org/10.1016/S1470-2045(23)00411-4

WU X , XIA L , ZHANG K , et al . Camrelizumab plus famitinib versus camrelizumab alone and investigator’s choice of chemotherapy in women with recurrent or metastatic cervical cancer [J ] . Ann Oncol , 2023 , 34 : S1284 -S1285.

LEE J Y , WU L , BOONYAPIPAT S , et al . AdvanTIG-202: phaseⅡ randomized, multicenter, open-label study of tislelizumab (TIS) with or without ociperlimab (OCI) in patients (pts) with previously treated recurrent/metastatic (R/M) cervical cancer (CC) [J ] . Ann Oncol , 2023 , 34 : S509 -S510.

VERGOTE I B , GONZALEZ MARTIN A , FUJIWARA K , et al . InnovaTV 301/ENGOT-cx12/GOG-3057: a global, randomized, open-label, phase Ⅲ study of tisotumab vedotin vs investigator’s choice of chemotherapy in 2L or 3L recurrent or metastatic cervical cancer [J ] . Ann Oncol , 2023 , 34 : S1276 -S1277.

XIA B , JIANG W , CHEN J , et al . Pamiparib combined with surufatinib as a neoadjuvant therapy for advanced ovarian cancer patients in the entire population: Preliminary results of a prospective, exploratory, single-arm phase Ⅱ clinical study [J ] . Ann Oncol , 2023 , 34 : S520 .

National Comprehensive Cancer Network . NCCN Guidelines for treatment of ovarian cancer, 2023 V2 [EB/OL ] . [2023-11-15 ] . https://www.nccn.org. https://www.nccn.org https://www.nccn.org

中国抗癌协会妇科肿瘤专业委员会 , 中国抗癌协会肿瘤多学科诊疗(MDT)专业委员会 , 中国医师协会肿瘤多学科诊疗专业委员会 . 妇科恶性肿瘤多学科诊疗中国专家共识(2022年版) [J ] . 中国癌症杂志 , 2022 , 32 ( 8 ): 747 - 756 . DOI: 10.19401/j.cnki.1007-3639.2022.08.010 http://doi.org/10.19401/j.cnki.1007-3639.2022.08.010

The Society of Gynecological Cancer of China Anti-Cancer Association, Multidisciplinary Diagnosis and Treatment (MDT) Committee of China Anti-Cancer Association , Multidisciplinary Cancer Diagnosis and Treatment Committee of Chinese Medical Doctor Association . Consensus of Chinese experts on multidisciplinary team of gynecological malignant tumors (2022 edition) [J ] . Chin Oncol , 2022 , 32 ( 8 ): 747 - 756 . DOI: 10.19401/j.cnki.1007-3639.2022.08.010 http://doi.org/10.19401/j.cnki.1007-3639.2022.08.010

WU X H , LIU J H , WANG X B , et al . Efficacy and safety of senaparib as maintenance treatment in patients with newly diagnosed advanced ovarian cancer (FLAMES study): a randomized, double-blind, placebo-controlled, phase 3 trial [C ] . Late Breaking Abstracts. BMJ Publishing Group Ltd , 2023 .

FLOOR B , TIRZA A C B , JESSICA P , et al . Real-world time to treatment discontinuation of first-line maintenance niraparib monotherapy in epithelial ovarian cancer: CHAR1ZMA study [C ] . 2023 ESMO, Abs 789P .

KURTZ J E , PUJADE-LAURAINE E , OAKNIN A , et al . Atezolizumab combined with bevacizumab and platinum-based therapy for platinum-sensitive ovarian cancer: placebo-controlled randomized phase Ⅲ ATALANTE/ENGOT-ov29 trial [J ] . J Clin Oncol , 2023 , 41 ( 30 ): 4768 - 4778 . DOI: 10.1200/JCO.23.00529 http://doi.org/10.1200/JCO.23.00529 https://ascopubs.org/doi/10.1200/JCO.23.00529 https://ascopubs.org/doi/10.1200/JCO.23.00529

PUJADE-LAURAINE E , FUJIWARA K , LEDERMANN J A , et al . Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study [J ] . Lancet Oncol , 2021 , 22 ( 7 ): 1034 - 1046 . DOI: 10.1016/S1470-2045(21)00216-3 http://doi.org/10.1016/S1470-2045(21)00216-3 https://linkinghub.elsevier.com/retrieve/pii/S1470204521002163 https://linkinghub.elsevier.com/retrieve/pii/S1470204521002163

HARTER P , TRILLSCH F , OKAMOTO A , et al . Durvalumab with paclitaxel/carboplatin (PC) and bevacizumab (bev), followed by maintenance durvalumab, bev, and olaparib in patients (pts) with newly diagnosed adva nced ovarian cancer (AOC) without a tumor BRCA 1/2 mutation (non-tBRCAm): results from the randomized, placebo (pbo)-controlled phase Ⅲ DUO-O trial [J ] . J Clin Oncol , 2023 , 41 ( 17_suppl ): LBA5506 . DOI: 10.1200/JCO.2023.41.17_suppl.LBA5506 http://doi.org/10.1200/JCO.2023.41.17_suppl.LBA5506 https://ascopubs.org/doi/10.1200/JCO.2023.41.17_suppl.LBA5506 https://ascopubs.org/doi/10.1200/JCO.2023.41.17_suppl.LBA5506

GONZALEZ MARTIN A , RUBIO PEREZ M J , HEITZ F , et al . Atezolizumab (atezo) combined with platinum-based chemotherapy (CT) and maintenance niraparib for recurrent ovarian cancer (rOC) with a platinum-free interval (TFIp) >6 months: primary analysis of the double-blind placebo (pbo)-controlled ENGOT-Ov41/GEICO 69-O/ANITA phase Ⅲ trial [J ] . Ann Oncol , 2023 , 34 : S1278 -S1279. DOI: 10.1016/j.annonc.2023.10.031 http://doi.org/10.1016/j.annonc.2023.10.031 https://linkinghub.elsevier.com/retrieve/pii/S0923753423041753 https://linkinghub.elsevier.com/retrieve/pii/S0923753423041753

LIU J F , BRADY M , MATULONIS U A , et al . Overall survival (OS) outcomes from NRG-GY004, a phase Ⅲ study comparing single-agent olaparib or combination cediranib and olaparib to platinum (Plat) based chemotherapy in recurrent plat sensitive ovarian cancer (OvCa) [J ] . Ann Oncol , 2023 , 34 : S1285 . DOI: 10.1016/j.annonc.2023.10.039 http://doi.org/10.1016/j.annonc.2023.10.039 https://linkinghub.elsevier.com/retrieve/pii/S0923753423041832 https://linkinghub.elsevier.com/retrieve/pii/S0923753423041832

LIU J F , BARRY W T , BIRRER M , et al . Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study [J ] . Lancet Oncol , 2014 , 15 ( 11 ): 1207 - 1214 . DOI: 10.1016/S1470-2045(14)70391-2 http://doi.org/10.1016/S1470-2045(14)70391-2

WU X , LIU J , WANG L , et al . SABRINA study: a phase Ⅱ study of senaparib monotherapy for patients (pts) with BRCA 1/2 mutated recurrent platinum-sensitive ovarian cancer (PSOC) [J ] . Ann Oncol , 2023 , 34 : S521 .

LEE J M . Randomized phase Ⅱ trial of durvalumab in combination with olaparib and cediranib (DOC) compared to olaparib and cediranib (OC) or durvalumab and cediranib (DC) or standard of care chemotherapy (SOC) in platinum-resistant ovarian cancer with prior bevacizumab (NRG-GY023) [J ] . Ann Oncol , 2023 , 34 : S511 .

MOORE K N , PHILIPOVSKIY A , HARANO K , et al . Raludotatug deruxtecan (R-DXd; DS-6000) monotherapy in patients with previously treated ovarian cancer (OVC): subgroup analysis of a first-in-human phase Ⅰ study [J ] . Ann Oncol , 2023 , 34 : S510 . DOI: 10.1016/j.annonc.2023.09.1924 http://doi.org/10.1016/j.annonc.2023.09.1924 https://linkinghub.elsevier.com/retrieve/pii/S0923753423027618 https://linkinghub.elsevier.com/retrieve/pii/S0923753423027618

HOWLETT S , BERNER A M , CONNOLLY K , et al . Response to chemotherapy following PARP inhibition in UK ovarian cancer (OC) patients [J ] . Ann Oncol , 2023 , 34 : S535 .

DE BRUYN M , EERKENS A L , BRUMMEL K , et al . Neoadjuvant immune checkpoint blockade in mismatch repair deficient endometrial cancer [J ] . Ann Oncol , 2023 , 34 : S508 -S509.

MIRZA M R , SHARMA S , HERRSTEDT J , et al . Dostarlimab+chemotherapy for the treatment of primary advanced or recurrent endometrial cancer (pA/rEC): analysis of progression free survival (PFS) and overall survival (OS) outcomes by molecular classification in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial [J ] . Ann Oncol , 2023 , 34 : S507 . DOI: 10.1016/j.annonc.2023.09.1919 http://doi.org/10.1016/j.annonc.2023.09.1919 https://linkinghub.elsevier.com/retrieve/pii/S0923753423027564 https://linkinghub.elsevier.com/retrieve/pii/S0923753423027564

ESKANDER R N , SILL M , MILLER A , et al . Updated response data and analysis of progression free survival by mechanism of mismatch repair loss in endometrial cancer (EC) patients (pts) treated with pembrolizumab plus carboplatin/paclitaxel (CP) as compared to CP plus placebo (PBO) in the NRG GY018 trial [J ] . Ann Oncol , 2023 , 34 : S1284 .

NICOLETTA C . Phase Ⅲ double-blind randomized placebo controlled trial of atezolizumab in combination with carboplatin and paclitaxel in women with advanced/recurrent endometrial carcinoma: ENGOT-en7/MaNGO/AtTEnd study [C ] . 2023 ESMO, Abs LBA40.

WESTIN S N , MOORE K N , CHON H S , et al . Durvalumab (durva) plus carboplatin/paclitaxel (CP) followed by maintenance (mtx) durva±olaparib (ola) as a first-line (1L) treatment for newly diagnosed advanced or recurrent endometrial cancer (EC): results from the phase Ⅲ DUO-E/GOG-3041/ENGOT-EN10 trial [J ] . Ann Oncol , 2023 , 34 : S1282 -S1283. DOI: 10.1016/j.annonc.2023.10.035 http://doi.org/10.1016/j.annonc.2023.10.035 https://linkinghub.elsevier.com/retrieve/pii/S0923753423041790 https://linkinghub.elsevier.com/retrieve/pii/S0923753423041790

JOLY LOBBEDEZ F , LEARY A , RAY-COQUARD I L , et al . Olaparib vs placebo as maintenance therapy after platinum-based chemotherapy in advanced/metastatic endometrial cancer patients: the GINECO randomized phase Ⅱb UTOLA trial [J ] . Ann Oncol , 2023 , 34 : S1283 -S1284. DOI: 10.1016/j.annonc.2023.10.036 http://doi.org/10.1016/j.annonc.2023.10.036 https://linkinghub.elsevier.com/retrieve/pii/S0923753423041807 https://linkinghub.elsevier.com/retrieve/pii/S0923753423041807

POTHURI B , NAUMANN R W , MARTIN L P , et al . Luveltamab tazevibulin (STRO-002), an anti-folate receptor alpha (FolRα) antibody drug conjugate (ADC), demonstrates clinical activity in recurrent/progressive epithelial endometrial cancer (EEC): STRO-002-GM1 phase Ⅰ dose expansion [J ] . Ann Oncol , 2023 , 34 : S508 .